These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Scleroderma--clinical and pathological advances. Denton CP; Black CM Best Pract Res Clin Rheumatol; 2004 Jun; 18(3):271-90. PubMed ID: 15158741 [TBL] [Abstract][Full Text] [Related]
10. The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. Clements P; Lachenbruch P; Furst D; Paulus H Arthritis Rheum; 1993 Nov; 36(11):1575-9. PubMed ID: 8240434 [TBL] [Abstract][Full Text] [Related]
11. Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials. Pope JE; Bellamy N Clin Invest Med; 1995 Feb; 18(1):1-10. PubMed ID: 7768060 [TBL] [Abstract][Full Text] [Related]
12. Systemic sclerosis and localized scleroderma in childhood. Zulian F Rheum Dis Clin North Am; 2008 Feb; 34(1):239-55; ix. PubMed ID: 18329543 [TBL] [Abstract][Full Text] [Related]
13. Outcome measures in systemic sclerosis: an update on instruments and current research. Khanna D; Merkel PA Curr Rheumatol Rep; 2007 May; 9(2):151-7. PubMed ID: 17502046 [TBL] [Abstract][Full Text] [Related]
14. Nodular scleroderma: focally increased tenascin expression differing from that in the surrounding scleroderma skin. Mizutani H; Taniguchi H; Sakakura T; Shimizu M J Dermatol; 1995 Apr; 22(4):267-71. PubMed ID: 7541812 [TBL] [Abstract][Full Text] [Related]
15. Emerging targeted therapies in scleroderma lung and skin fibrosis. Maurer B; Distler O Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265 [TBL] [Abstract][Full Text] [Related]